Abstract
Obesity is a chronic disease characterized by the accumulation of excess adipose tissue associated with an increased risk of multiple morbidities and mortality. At the present time, only three drugs have been approved by the Food and Drug Administration (FDA) for the treatment of obesity. Agonists and antagonists of some of the substances implicated in the regulation of energy homeostasis represent opportunities for anti-obesity drug development. The most promising targets are alpha-melanocyte stimulating hormone (alpha- MSH) receptors, cannabinoid receptors, the 5-hydroxytryptamine (5-HT) receptors and melanin-concentrating hormone (MCH) receptors. MCH receptors could be major potential targets for the treatment of obesity. Many pharmaceutical companies have described MCH-R1 antagonists that have appeared over the past year. Recently, two compounds went into phase I clinical trials that evaluate MCH receptor antagonists as a new perspective for the pharmacologic treatment of obesity. In this review, structure-activity relationships (SAR) in the development of MCH-R1 antagonists are provided.
Keywords: Antagonists, melanin-concentrating hormone (MCH), melanin-concentrating hormone receptor 1 (MCH-R1), structure-activity relationship (SAR), obesity
Current Medicinal Chemistry
Title: Melanin-Concentrating Hormone Receptor 1 Antagonists: A New Perspective for the Pharmacologic Treatment of Obesity
Volume: 15 Issue: 10
Author(s): Gildardo Rivera, Virgilio Bocanegra-Garcia, Silvia Galiano, Nuria Cirauqui, Javier Ceras, Silvia Perez, Ignacio Aldana and Antonio Monge
Affiliation:
Keywords: Antagonists, melanin-concentrating hormone (MCH), melanin-concentrating hormone receptor 1 (MCH-R1), structure-activity relationship (SAR), obesity
Abstract: Obesity is a chronic disease characterized by the accumulation of excess adipose tissue associated with an increased risk of multiple morbidities and mortality. At the present time, only three drugs have been approved by the Food and Drug Administration (FDA) for the treatment of obesity. Agonists and antagonists of some of the substances implicated in the regulation of energy homeostasis represent opportunities for anti-obesity drug development. The most promising targets are alpha-melanocyte stimulating hormone (alpha- MSH) receptors, cannabinoid receptors, the 5-hydroxytryptamine (5-HT) receptors and melanin-concentrating hormone (MCH) receptors. MCH receptors could be major potential targets for the treatment of obesity. Many pharmaceutical companies have described MCH-R1 antagonists that have appeared over the past year. Recently, two compounds went into phase I clinical trials that evaluate MCH receptor antagonists as a new perspective for the pharmacologic treatment of obesity. In this review, structure-activity relationships (SAR) in the development of MCH-R1 antagonists are provided.
Export Options
About this article
Cite this article as:
Rivera Gildardo, Bocanegra-Garcia Virgilio, Galiano Silvia, Cirauqui Nuria, Ceras Javier, Perez Silvia, Aldana Ignacio and Monge Antonio, Melanin-Concentrating Hormone Receptor 1 Antagonists: A New Perspective for the Pharmacologic Treatment of Obesity, Current Medicinal Chemistry 2008; 15 (10) . https://dx.doi.org/10.2174/092986708784049621
DOI https://dx.doi.org/10.2174/092986708784049621 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cellular and Physiological Effects of Arginine
Mini-Reviews in Medicinal Chemistry Henoch-Schönlein Purpura in Children: An Updated Review
Current Pediatric Reviews Drug-Induced Anemia and Other Red Cell Disorders: A Guide in the Age of Polypharmacy
Current Clinical Pharmacology New Oral Anticoagulants in Prophylaxis of Venous Thromboembolic Disease in Major Orthopedic Surgery
Cardiovascular & Hematological Disorders-Drug Targets Regeneration in Tetrapleura tetraptera via Indirect Somatic Embryogenesis from Isolated Axillary Meristems
Current Biotechnology Is Atherothromboaspiration a Possible Solution for the Prevention of No-Reflow Phenomenon in Acute Coronary Syndromes? Single Centre Experience and Review of the Literature
Current Vascular Pharmacology Mechanisms of Action of Metformin in Type 2 Diabetes and Associated Complications: An Overview
Mini-Reviews in Medicinal Chemistry Metabolic Profile of Flunitrazepam: Clinical and Forensic Toxicological Aspects
Drug Metabolism Letters Hallmarks in the Therapeutic Approach of Aortic Aneurysms: The Main Contributors
Current Pharmaceutical Design Development of Gene Therapies for Cardiovascular and Renal Diseases by Nucleic Acid Medicines
Medicinal Chemistry Understanding the Molecular and Cellular Changes Behind Aortic Valve Stenosis
Current Pharmaceutical Biotechnology Aqueous Extract of Argania spinosa L. Fruits Ameliorates Diabetes in Streptozotocin-Induced Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of Venous Abnormalities in Neurological Disease
Reviews on Recent Clinical Trials Androgen Deficiency in Aging Male Questionnaire for the Clinical Detection of Testosterone Deficiency in a Population of Black Sub-Saharan African Men with Type 2 Diabetes Mellitus: Is it a Reliable Tool?
Current Diabetes Reviews Vascular and Cardiac Oxidative Stress and Inflammation as Targets for Cardioprotection
Current Pharmaceutical Design Vitamin D and Cardiovascular Disease
Current Vascular Pharmacology Current Development in Tissue-Engineered Vascular Grafts
Vascular Disease Prevention (Discontinued) Editorial [Hot Topic: Role of Oxidative-Nitrostative Stress and Poly(ADP-ribose) Polymerase in Cardiovascular Pathophysiology (Guest Editor: Pal Pacher)]
Current Vascular Pharmacology Vascular Dysfunction in Hypertensive Disorders
Current Hypertension Reviews Severe Hyponatremia and Other Electrolyte Disturbances Associated with Indapamide
Current Drug Safety